Radiopharm Theranostics (ASX:RAD) completed the preclinical package for its radiotherapeutic product 161 terbium-labeled RAD 402, or 161Tb-Rad 402, according to a Tuesday filing with the Australian bourse.
Preclinical toxicology studies showed no adverse effects, while biodistribution reports showed minimal uptake in the kidney and bone marrow with high-prostate cancer tumor targeting in mice models, the filing said.
The biopharmaceutical firm is expected to conduct its first-in-human trials for the product by the second half of 2025, per the filing.
Company shares slumped 17% in recent Tuesday trade.
Price (AUD): $0.03, Change: $-0.01, Percent Change: -17.07%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。